The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Differences between menin inhibitors that are approved or under investigation for AML
In this video, Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, briefly discusses aspects that differentiate menin inhibitors that are approved or under investigation for acute myeloid leukemia (AML). Dr Fathi notes that while some differences in tolerability profiles and dosing schedules exist, the most significant factors differentiating these agents will likely be efficacy and convenience. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
It’s hard to know. I mean, I think some of the menin inhibitors are farther along. Some are still in clinical trials and additional numbers of patients are being treated. So it is difficult to know whether truly the rates of composite remission or CR plus CRh or CR are going to be that different from one another. They may be, but time will tell. There are some differences in sort of the tolerability profiles of the different menin inhibitors...
It’s hard to know. I mean, I think some of the menin inhibitors are farther along. Some are still in clinical trials and additional numbers of patients are being treated. So it is difficult to know whether truly the rates of composite remission or CR plus CRh or CR are going to be that different from one another. They may be, but time will tell. There are some differences in sort of the tolerability profiles of the different menin inhibitors. Revumenib, for example, is associated with QT prolongation. Ziftomenib has a signal for itching. There are differences in dosing and schedule. Revumenib has different doses for concomitant use of CYP3A agents. It is twice daily, whereas Ziftomenib is once daily. The other drugs that are being developed also have their unique features. There is a class effect with differentiation syndrome that seems to be similar across the various different types of menin inhibitors. I think as we get more of these in play, probably the most likely thing to impact the differentiation between these is efficacy or activity, if there is indeed a difference in activity, followed by convenience for patients and tolerability.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
